MedicalFoundationOfNC.org Editorial Team | Updated April 2026
This article is for general informational purposes only and does not constitute medical advice. All options discussed below require medical evaluation and, where applicable, a valid prescription from a licensed healthcare provider. Consult a healthcare professional to determine what, if anything, is appropriate for your situation. Pricing reflects published information as of April 2026 and is subject to change.
Quick Answer: As of April 2026, adults evaluating oral GLP-1 options have two FDA-approved pills: the Wegovy pill (oral semaglutide, ~14% mean weight loss, requires 30-min morning fasting window, $149/mo starter self-pay) and Foundayo (orforglipron, ~8–9% mean weight loss in trials, no fasting or food restrictions, $149/mo starting self-pay). For injectable options with higher efficacy, Zepbound (tirzepatide) leads at ~21% mean weight loss, and Wegovy HD (7.2 mg injection) was approved March 19, 2026 at ~20.7%. No head-to-head trials directly compare these options — all numbers are from separate trials with different patient populations. The right choice depends on your medical eligibility, lifestyle, and insurance.
The GLP-1 weight loss field changed twice in four months. The Wegovy pill was FDA-approved in December 2025. Foundayo (orforglipron) — the second oral GLP-1 for obesity — was FDA-approved in April 2026. Wegovy HD, a higher-dose injectable, was approved March 19, 2026. Three new approvals in one season. If you've been trying to keep up, you're not alone — and the question of which option actually makes sense for your situation has gotten genuinely more complicated to answer.
Each option has a different profile of evidence, cost, access requirements, and practical considerations. This guide lays out the options clearly and honestly — not to steer you anywhere specific, but to help you understand what the real differences are so your conversation with a provider is more productive.
The Options: A Clear Overview
Here's where each path stands in 2026:
Wegovy pill (oral semaglutide 25 mg) — FDA-approved December 2025: Once-daily oral tablet. No refrigeration required. 30-minute fasting window before taking. Approved for adults 18+ with obesity (BMI 30+) or overweight (BMI 27+) with a weight-related condition. OASIS 4 trial showed approximately 14% mean weight loss at 64 weeks (treatment-policy analysis). Available at retail pharmacies and through select telehealth platforms. Self-pay starting at $149/month for starter doses through August 2026; list price ~$1,349/month. With eligible commercial insurance savings card: as little as $25/month.
Wegovy injection (semaglutide 2.4 mg) — FDA-approved 2021: Once-weekly injection. Refrigeration required. Larger evidence base — STEP 1 trial enrolled over 1,900 participants and showed approximately 15% mean weight loss at 68 weeks. The SELECT trial additionally established a reduction in major adverse cardiovascular events in adults with obesity and established cardiovascular disease. FDA-approved for adolescents 12+ with obesity. List price ~$1,349/month. Same Novo Nordisk savings card applies: $25/month with eligible commercial insurance. Important 2026 update: The FDA approved Wegovy HD (7.2 mg injection) on March 19, 2026, for adults who've tolerated 2.4 mg maintenance for at least four weeks and need additional weight reduction. The STEP UP trial showed approximately 20.7% mean weight loss at the higher dose. No equivalent higher-dose option exists for the pill.
Zepbound (tirzepatide) — FDA-approved 2023: Once-weekly injection. Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both GIP and GLP-1 receptors, compared to semaglutide's GLP-1-only action. SURMOUNT-1 trial data showed approximately 21% mean weight loss at 72 weeks in participants without diabetes, making tirzepatide the highest-efficacy injectable weight loss medication currently on the market. Refrigeration required. Adult indication only. Available at retail pharmacies. Our dedicated Wegovy vs Foundayo vs Zepbound comparison covers these three options in more depth.
Compounded semaglutide or tirzepatide (telehealth programs): During the FDA-designated shortage period for branded Wegovy and Zepbound, FDA-registered compounding pharmacies were legally permitted to produce compounded versions of semaglutide and tirzepatide. The FDA has determined that the shortage has ended for both semaglutide and tirzepatide — meaning that, as of early 2026, most compounding pharmacies are no longer permitted to produce these compounds for standard commercial distribution. Some 503B outsourcing facilities may continue under more limited circumstances. Compounded medications are not FDA-approved as finished products. If you're evaluating a compounded pathway, confirming the current regulatory status of the specific program you're considering is essential. Our MEDVi platform overview covers one established telehealth program in this space and its current positioning.
Foundayo (orforglipron): Also an oral GLP-1, but a fundamentally different type. While the Wegovy pill is an oral peptide (a protein-based molecule that requires the SNAC absorption technology and a fasting window), Foundayo is a small-molecule oral GLP-1 receptor agonist — a synthetic non-peptide compound that activates the same GLP-1 receptor without being a protein. Because it's not a peptide, it doesn't need SNAC technology, doesn't require refrigeration, and — importantly — doesn't have a fasting or 30-minute waiting requirement. You can take it with food, with water, at any time of day. Foundayo was FDA-approved under the brand name Foundayo (orforglipron) by Eli Lilly. In an indirect comparison presented at the Obesity Medicine Association in April 2026, Novo Nordisk's own researchers reported oral semaglutide 25 mg produced greater mean weight loss than orforglipron 36 mg (the phase 3 trial dose equivalent), though the two drugs have different approved doses and have not been directly compared head-to-head in a prospective trial. For a full breakdown of Foundayo's mechanism, trial data, and how it compares to the Wegovy pill, see our Foundayo 2026 guide and our full GLP-1 comparison.
Wegovy Pill vs Foundayo vs Zepbound: How Should You Compare Them?
The right question isn't “which one works best?” as if there were a universal answer. The right questions are: which one you are medically eligible for, which one fits your access and cost situation, and which one you'll actually be able to take consistently over time.
On those dimensions, here's an honest analysis:
Which GLP-1 Produces the Most Weight Loss — Wegovy Pill, Foundayo, or Zepbound?
No direct head-to-head trials exist between oral Wegovy and injectable Wegovy, or between oral Wegovy and Zepbound. Comparisons across trials require caution because trial populations, protocols, and outcome definitions differ. With that caveat:
Tirzepatide (Zepbound) has produced the highest weight loss numbers in published trials — approximately 21% at 72 weeks in SURMOUNT-1. This is a meaningful efficacy advantage over injectable semaglutide (approximately 15% at 68 weeks in STEP 1) and oral semaglutide (approximately 14% at 64 weeks in OASIS 4).
The differences between injectable semaglutide and oral semaglutide outcomes are within a range that may reflect population and protocol differences as much as formulation differences. The active molecule is the same; the delivery achieves comparable therapeutic exposures at appropriate doses.
For people who specifically need the highest available efficacy and are appropriate candidates for injectable treatment, tirzepatide's data is currently strongest. For people for whom the injection format is a barrier, oral semaglutide's efficacy in OASIS 4 is clinically meaningful and comparable to the injectable semaglutide range.
On the oral-only comparison: in an indirect treatment comparison presented at the Obesity Medicine Association in April 2026, Novo Nordisk researchers reported oral semaglutide 25 mg produced significantly greater mean weight loss than orforglipron 36 mg (the phase 3 equivalent of Foundayo's approved dose). This is an industry-funded indirect comparison, not a head-to-head trial, so it should be read with appropriate caution — but it is the most current data point available for comparing the two oral GLP-1 options.
How Much Does Each Option Cost in 2026 — With and Without Insurance?
The cost picture in 2026 is more complicated than headlines suggest. Published list prices for branded GLP-1 medications are not what most people pay — but what you actually pay depends heavily on your insurance situation.
With eligible commercial insurance and the Novo Nordisk savings card: Both oral and injectable Wegovy can cost as little as $25/month. Zepbound/Eli Lilly has a comparable program. Coverage varies by plan and most require prior authorization.
Without insurance, self-pay through manufacturer programs: Oral Wegovy's introductory program through NovoCare Pharmacy offers starter doses at $149/month through August 2026. Injectable Wegovy's self-pay pricing through NovoCare has run in the $349–$499/month range depending on dose and timing of purchase. Zepbound's self-pay pricing has been comparable to injectable Wegovy.
Foundayo (orforglipron) self-pay: Starting at $149/month for the entry dose as of April 2026 launch, with higher doses at higher prices. Eli Lilly has a comparable savings card program for commercially insured patients: as little as $25/month. No list price published as of April 2026 launch. Medicare coverage expected starting July 2026 at approximately $50/month for qualifying patients.
Compounded pathways: Compounded semaglutide programs, when legally available during the shortage period, were offered at prices ranging from roughly $179 to $350/month through various telehealth platforms. With the FDA's determination that the shortage has ended, the legal pathway for standard commercial compounding has narrowed substantially. Anyone evaluating a current compounded program should verify the program's specific regulatory basis.
Retail without any program: All branded GLP-1 weight loss medications carry list prices in the $1,300–$1,700/month range. GoodRx and similar pharmacy discount programs reduce this modestly but typically not to a level that makes them accessible for most uninsured individuals long-term.
Which GLP-1 Is Easiest to Access in 2026?
All prescription options require a licensed clinician to evaluate eligibility and write a prescription. The route to that prescription differs.
Telehealth has substantially reduced the friction of getting a GLP-1 prescription — platforms like Ro, LifeMD, and Weight Watchers now provide clinician evaluation and prescription services entirely online for oral and injectable Wegovy. The same platforms that previously enabled compounded semaglutide access are in various states of transition as the regulatory environment for compounded options has tightened.
Oral Wegovy is available at 70,000+ US retail pharmacies as of January 2026. Supply is no longer the constraint it was during peak Wegovy injection shortage periods.
Which Option Is Right for You? A Decision Framework
If maximum documented efficacy is the priority and injectable format isn't a barrier: tirzepatide (Zepbound) has the strongest weight loss data available. Review our Wegovy vs Foundayo vs Zepbound comparison for the detailed head-to-head.
If avoiding injection entirely is essential: oral Wegovy is now the first and only FDA-approved oral GLP-1 for obesity. Its efficacy is clinically meaningful and comparable to injectable semaglutide range. The 30-minute fasting requirement is a real daily consideration. Foundayo (orforglipron) offers a second oral GLP-1 option without the fasting window — our Foundayo 2026 guide covers the tradeoffs in detail.
If cost is the primary driver: the comparison depends entirely on your insurance status. With commercial insurance and a savings card, both oral and injectable branded options can reach $25/month. Without insurance, the self-pay picture has changed with the narrowing of compounded options — the $149/month introductory oral Wegovy program through August 2026 is currently among the most accessible branded entry points.
If you've previously tried injectable semaglutide and stopped specifically because of the injection experience, the oral formulation is directly relevant — same molecule, same mechanism, meaningfully different administration experience. That conversation is worth having with your prescriber.
If you're on Medicare or Medicaid, the manufacturer savings programs generally don't apply. Coverage for GLP-1 weight loss medications through government programs remains limited as of April 2026, though it's an evolving area — potential mid-2026 Medicare expansion for specific eligible patients has been discussed publicly.
The Bottom Line
The 2026 GLP-1 field offers more options than at any previous point — and more complexity. The Wegovy pill is a genuinely new development: the first oral GLP-1 for obesity, broadly available, with a meaningful safety record inherited from semaglutide's years of use. It doesn't outperform injectable tirzepatide on raw efficacy data. It does offer a format that removes the injection barrier for people for whom that matters.
The right path is personal, medical, and financial. The purpose of this comparison is to give you a clear enough picture of the current options that your conversation with a healthcare provider can be more specific — not to make the decision for you.
For deeper reading on specific options: Wegovy pill complete guide (oral semaglutide 2026) | Full GLP-1 comparison: Foundayo vs Wegovy vs Zepbound | Foundayo 2026 guide | MEDVi platform overview
All efficacy figures cited are from the respective FDA registration trials (OASIS 4, STEP 1, SURMOUNT-1) as reported in peer-reviewed publications and FDA prescribing information. Pricing information is based on published manufacturer disclosures as of April 2026 and is subject to change. Compounding regulatory information is based on FDA communications regarding shortage designations as of early 2026. This is not medical advice.